Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Active Biotech ABFRA:BTP +1.51%34 3-1 Month Momentum % is -16.39% as of Jul. 24, 2026. GuruFocus rates FRA:BTP with a GF Score™ of 34/100 and a GF Value™ of €0.13 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,392 Biotechnology companies, Active Biotech AB ranks worse than 58.05% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-24), Active Biotech AB's 3-1 Month Momentum % is -16.39%.
The industry rank for Active Biotech AB's 3-1 Month Momentum % or its related term are showing as below:
FRA:BTP's 3-1 Month Momentum % is ranked worse than 58.05% of 1392
companies
in the Biotechnology industry
Industry Median: -10.615
vs FRA:BTP: -16.39
Active Biotech AB (FRA:BTP) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Active Biotech AB 3-1 Month Momentum % Related Terms
FRA:BTP vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Active Biotech AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Active Biotech AB 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Active Biotech AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Active Biotech AB's 3-1 Month Momentum % falls into.
Active Biotech AB (FRA:BTP) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Active Biotech AB (FRA:BTP) has a 3-1 Month Momentum % of -16.39% as of Jul. 24, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Active Biotech AB and its competitors. According to the industry distribution chart, Active Biotech AB ranks #808 out of 1392 companies in the Biotechnology industry, placing it in the top 58%.
Is Active Biotech AB's 3-1 Month Momentum % too high?
Active Biotech AB's current 3-1 Month Momentum % is -16.39%. Based on the distribution chart, Active Biotech AB ranks #808 out of 1392 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Active Biotech AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Active Biotech AB ranks #808 out of 1392 companies for 3-1 Month Momentum %. This places Active Biotech AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Active Biotech AB and its competitors. Active Biotech AB's current 3-1 Month Momentum % is -16.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Based on GuruFocus' analysis, Active Biotech AB (FRA:BTP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.47 — trading 262.7% above its estimated fair value. The current 3-1 Month Momentum % is -16.39%. Active Biotech AB's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Active Biotech AB (FRA:BTP), the current 3-1 Month Momentum % is -16.39% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Active Biotech AB (FRA:BTP) Overvalued in 2026?
Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued.
The current stock price of €0.47 is trading 262.7% above its estimated GF Value™ of €0.13.
GuruFocus considers Active Biotech AB to be Significantly Overvalued.
Key valuation signals for FRA:BTP:
3-1 Month Momentum %: -16.39%
GF Value™: €0.13 vs. price of €0.47 (262.7% above fair value)
No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
34GF Score
Get the complete analysis for FRA:BTP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BTP has been successfully added to your 
